hVIVO (LON:HVO) Stock Price Up 8% – What’s Next?

hVIVO plc (LON:HVO) shares rose 8% during mid-day trading on Wednesday . The company traded as high as GBX 6.50 and last traded at GBX 6.48. Approximately 1,554,628 shares changed hands during mid-day trading, a decline of 38% from the average session volume of 2,515,174 shares. The stock had previously closed at GBX 6.

hVIVO Stock Up 8.0%

The company has a debt-to-equity ratio of 43.38, a quick ratio of 1.16 and a current ratio of 1.21. The stock’s fifty day simple moving average is GBX 6.71 and its two-hundred day simple moving average is GBX 7.32. The stock has a market capitalization of £44.59 million, a P/E ratio of -7.45 and a beta of 1.69.

hVIVO (LON:HVO) last posted its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.82) EPS for the quarter. hVIVO had a negative return on equity of 35.13% and a negative net margin of 31.76%. As a group, research analysts expect that hVIVO plc will post 1.5492958 EPS for the current fiscal year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.